Virbac Q1 2026: 7.7% Revenue Surge Driven by Supercharge4 Dewormer GrowthVirbac’s Q1 2026 revenue up 7.7% as Supercharge4 drives double‑digit growth in the booming global dewormer market.Virbac SACA Health Care Pharmaceuticals, Biotechnology & Life Sciences AI generated 16/04/2026, 17:59 2 minutes to read
